Interested in Digital Strategy in Q4 2020? Download our FREE whitepaper on this topic. This is an exclusive promotion being run on LinkedIn.

  Please register (it's free!) or login to view the remaining preview.
If you are logged in, your referral link [?] is automatically included below.
EMBED CODE (Copy and Paste)


BENEFITS OF DOCUMENT

  1. The breast cancer therapy market was the largest in oncology across the major markets
  2. Etiology and Pathophysiology
  3. Key Pathways and Drug Targets

DOCUMENT DESCRIPTION

The breast cancer therapy market was the largest in oncology across the major markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) in 2015 with sales of $13.8 billion. Sales are set to soar throughout our forecast period to $30.5 billion by 2025, driven by uptake of both current and emerging agents in multiple treatment settings. Two drug classes, HER2-targeted agents and CDK4/6 inhibitors, will account for over 60% of sales in this market in 2025.

Currently approved therapies will continue to have a meaningful impact on the breast cancer treatment algorithm and market sales. Pfizer?s CDK4/6 inhibitor Ibrance will experience increasing use in the HR-positive, HER2-negative population, fueling this agent?s sales to exceed $8.5 billion at its peak. Roche/Genentech/Chugai?s HER2-targeted MAb, Perjeta, will continue to gain traction in the market, with its forecast adjuvant approval bolstering sales to exceed $5 billion in 2025.

Introduction
Key Findings
Market Share of Cancer Drug Classes in 2015 and 2025
Market SWOT Analysis
Etiology and Pathophysiology
Key Findings
Expert Insight
Pathophysiology
Anatomy
Subtypes
Staging and Classification
Key Pathways and Drug Targets
Market Outlook
Key Findings
Expert Insight
Market Overview
Market Drivers and Constraints
What Factors Are Driving the Market?
What Factors Are Constraining the Market?

Got a question about the product? Email us at [email protected] or ask the author directly by using the form to the right. If you cannot view the preview above this document description, go here to view the large preview instead.

Source: Market Overview: Breast Cancer PDF document

 

Market Overview: Breast Cancer

Sold by pharmzolgas (this author has 4 documents)

$299.00

ALL FEES INCLUDED
Add to Cart
  

This business document is categorized under the function(s):

It applies to Healthcare & Life Sciences

File Type: PDF (pdf)

File Size: 1.7 MB

Number of Pages: 29

Purchase includes lifetime product updates. After your purchase, you will receive an email to download this document.

Initial upload date (first version): Mar 8, 2017
Most recent version published: Mar 10, 2017

Ask the Author a Question

Must be logged in Click here to log in






CUSTOMER TESTIMONIALS




SELECT CUSTOMERS

Since 2012, we have provided best practices to over 5,000 businesses and organizations of all sizes across the world—in over 130 countries. Below is just a very small sample of our customer base.



Did you know?
The average daily rate of a McKinsey consultant is $6,625 (not including expenses). The average price of a Flevy document is $65.



CUSTOMERS ALSO BOUGHT THESE DOCUMENTS

1-page PDF document
$20.00
Author: Ivana Nissen
234-slide PowerPoint deck
$65.00
Author: Ivana Nissen
1-page PDF document
$30.00
901-slide PowerPoint deck
$45.00
50-slide PowerPoint deck
$129.00
57-slide PowerPoint deck
$99.00
29-page Word document
$249.00
Author: gmclennan
232-slide PowerPoint deck and supporting ZIP
$96.00

 
RELATED TOPICS

TOP 10 TOPICS

Become your organization's resident expert on...

Digital Transformation
 
Strategy Development
 
Organizational Design (OD)
 
Performance Management
 
Post-merger Integration (PMI)
 
Business Transformation
 
Organizational Culture (OC)
 
Customer-centric Design (CCD)
Interested in something else? Browse our 350+ Business Toolkits of best practices, each focused on a specific management topic.